Oberweis Asset Management Inc. Has $17.56 Million Position in Haemonetics Co. (NYSE:HAE)

Oberweis Asset Management Inc. boosted its position in shares of Haemonetics Co. (NYSE:HAE) by 26.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 224,920 shares of the medical instruments supplier’s stock after buying an additional 47,125 shares during the period. Oberweis Asset Management Inc.’s holdings in Haemonetics were worth $17,562,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the company. TD Waterhouse Canada Inc. bought a new stake in shares of Haemonetics during the 4th quarter worth $25,000. Covestor Ltd increased its position in Haemonetics by 146.8% during the 4th quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier’s stock worth $58,000 after purchasing an additional 439 shares in the last quarter. Whittier Trust Co. bought a new position in Haemonetics in the 4th quarter valued at approximately $62,000. Parkside Financial Bank & Trust lifted its stake in Haemonetics by 25.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock valued at $92,000 after purchasing an additional 240 shares during the last quarter. Finally, AlphaQuest LLC grew its stake in shares of Haemonetics by 36,520.0% during the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier’s stock worth $143,000 after buying an additional 1,826 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

Haemonetics Stock Up 2.1 %

Shares of NYSE HAE opened at $60.41 on Thursday. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. The firm has a market cap of $3.04 billion, a PE ratio of 23.79, a P/E/G ratio of 1.11 and a beta of 0.41. The company’s fifty day simple moving average is $62.87 and its 200 day simple moving average is $72.36. Haemonetics Co. has a 12-month low of $55.30 and a 12-month high of $97.97.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. As a group, sell-side analysts forecast that Haemonetics Co. will post 4.55 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HAE has been the topic of several recent research reports. Bank of America downgraded Haemonetics from a “neutral” rating to an “underperform” rating and cut their price objective for the company from $95.00 to $68.00 in a report on Friday, February 7th. Barrington Research reduced their target price on shares of Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Needham & Company LLC dropped their price target on shares of Haemonetics from $108.00 to $104.00 and set a “buy” rating for the company in a research note on Tuesday, March 18th. Raymond James reissued a “strong-buy” rating and issued a $115.00 price objective (down previously from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. Finally, StockNews.com downgraded Haemonetics from a “buy” rating to a “hold” rating in a report on Saturday, February 15th. One analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $101.22.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.